The Case for GNMT as a Biomarker and a Therapeutic Target in Pancreatic Cancer.

Zachary Heinzman, Connor Schmidt, Marek K Sliwinski, Nalin C W Goonesekere

Open access · goldAbstract read

In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

0.2field-weighted citation impact, top 48% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

GNMT and Its Regulatory MicroRNAs as Biomarkers and Therapeutic Targets for Metabolic Dysfunction-Associated Fatty Liver Disease and Hepatocellular Carcinoma.International journal of molecular sciences · 2026
Review
Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients.PloS one · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zachary HeinzmanDepartment of Chemistry and Biochemistry, University of Northern Iowa, Cedar Falls, IA 50614, USA.

Connor SchmidtDepartment of Chemistry and Biochemistry, University of Northern Iowa, Cedar Falls, IA 50614, USA.

Marek K SliwinskiDepartment of Biology, University of Northern Iowa, Cedar Falls, IA 50614, USA.

Nalin C W GoonesekereDepartment of Chemistry and Biochemistry, University of Northern Iowa, Cedar Falls, IA 50614, USA.

University of Northern Iowa · US

Funding

National Science Foundation 6052.00.24201.0000.21.0122

6 · The paper itself

Abstract

The high mortality rate for pancreatic cancer (PC) is due to the lack of specific symptoms at early tumor stages and a high biological aggressiveness. Reliable biomarkers and new therapeutic targets would help to improve outlook in PC. In this study, we analyzed the expression of GNMT in a panel of pancreatic cancer cell lines and in early-stage paired patient tissue samples (normal and diseased) by quantitative reverse transcription-PCR (qRT-PCR). We also investigated the effect of 1,2,3,4,6-penta-

Indexed as

1,2,3,4,6-penta-O-galloyl-β-d-glucopyranosidebiomarkerGNMTpancreatic cancer

Identifiers

PMID33802396

DOI10.3390/ph14030209

PMCPMC7998508

OpenAlexW3135323069

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.